Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Dice Therapeutics Inc (DICE)

Dice Therapeutics Inc (DICE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 709,196
  • Shares Outstanding, K 38,211
  • Annual Sales, $ 1,130 K
  • Annual Income, $ -48,960 K
  • 60-Month Beta N/A
  • Price/Sales 623.26
  • Price/Cash Flow N/A
  • Price/Book 2.52
Trade DICE with:

Options Overview Details

View History
  • Implied Volatility 208.33% ( -11.72%)
  • Historical Volatility 89.99%
  • IV Percentile 95%
  • IV Rank 88.74%
  • IV High 225.96% on 09/19/22
  • IV Low 69.45% on 03/24/22
  • Put/Call Vol Ratio 2.62
  • Today's Volume 438
  • Volume Avg (30-Day) 699
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 37,570
  • Open Int (30-Day) 30,345

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.61
  • Number of Estimates 3
  • High Estimate -0.61
  • Low Estimate -0.62
  • Prior Year -2.30
  • Growth Rate Est. (year over year) +73.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.08 +23.08%
on 08/31/22
23.61 -21.39%
on 09/09/22
-0.14 (-0.75%)
since 08/23/22
3-Month
14.41 +28.75%
on 07/13/22
23.61 -21.39%
on 09/09/22
+2.82 (+17.92%)
since 06/23/22
52-Week
12.64 +46.89%
on 06/16/22
38.18 -51.39%
on 11/18/21
-14.69 (-44.18%)
since 09/23/21

Most Recent Stories

More News
The Zacks Analyst Blog Highlights Absci Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics

Absci, Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics are part of Zacks top Analyst Blog.

AXLA : 1.6200 (-7.43%)
PLRX : 19.83 (-3.41%)
FRLN : 0.7695 (+11.94%)
ABSI : 3.11 (-4.31%)
DICE : 18.56 (+1.14%)
Why Earnings Season Could Be Great for DICE Therapeutics (DICE)

DICE Therapeutics (DICE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

DICE : 18.56 (+1.14%)
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

AXLA : 1.6200 (-7.43%)
PLRX : 19.83 (-3.41%)
FRLN : 0.7695 (+11.94%)
ABSI : 3.11 (-4.31%)
DICE : 18.56 (+1.14%)
DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of Psoriasis

Topline proof-of-concept data in healthy volunteers and psoriasis patients expected in 2H 2022 SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE...

DICE : 18.56 (+1.14%)
DICE Therapeutics to Present at the 2022 Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its...

DICE : 18.56 (+1.14%)
DICE Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its...

DICE : 18.56 (+1.14%)
Novartis Is Looking for Deals. Are These 3 Biotechs on Its List?

CEO Vas Narasimhan is seeking acquisitions under $2 billion.

NVS : 76.01 (-1.46%)
NKTX : 12.34 (-1.44%)
DICE : 18.56 (+1.14%)
IMCR : 43.50 (-0.46%)
ShouTi Appoints Sharon Tetlow to Board of Directors

ShouTi Inc ., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today announced the appointment of Sharon Tetlow to the company’s...

DICE : 18.56 (+1.14%)
VALN : 11.01 (-5.58%)
CBIO : 0.4894 (-5.79%)
DICE Therapeutics Expands Management Team and Board of Directors

Mary Riley, J.D., appointed as general counselLisa Bowers, MHSA, and Mittie Doyle, M.D., FACR, join board of directors SOUTH SAN FRANCISCO, Calif., March ...

DICE : 18.56 (+1.14%)
DICE Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

On track to deliver topline proof-of-concept data from Phase 1 clinical trial of oral IL-17 antagonist DC-806 in healthy volunteers and psoriasis patients...

DICE : 18.56 (+1.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

DICE Therapeutics Inc. is a biopharmaceutical company. Its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 20.89
2nd Resistance Point 19.77
1st Resistance Point 19.17
Last Price 18.56
1st Support Level 17.45
2nd Support Level 16.33
3rd Support Level 15.73

See More

52-Week High 38.18
Fibonacci 61.8% 28.42
Fibonacci 50% 25.41
Fibonacci 38.2% 22.39
Last Price 18.56
52-Week Low 12.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar